miR Scientific - Disease Management Platform
miR Scientific is a precision healthcare company committed to improving public health by transforming cancer management globally. The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers. The initial test delivered by the miR Disease Management Platform® is the miR Sentinel™ Prostate Cancer Test, the first and only standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and can monitor prostate cancer at the molecular level.
-
Most popular related searches
The miR Advantage
miR Sentinel’s accuracy and accessibility in diagnosing and classifying prostate cancer can meaningfully alleviate the economic and human burden of one of the world’s most prevalent and deadly diseases.
Our miR Sentinel™ Test uses precise biologic information interrogation techniques to categorize patients into one of four groups: no molecular evidence of prostate cancer, low-risk cancer, intermediate-risk cancer, or elevated risk cancer. This helps physicians determine which patients need treatment and which can be monitored, helping avoid harmful and costly over-treatment. Our highly accurate, easy-to-administer urine test is powered by our algorithm-based miR Disease Management Platform™ designed to help physicians diagnose and monitor patients across the continuum of cancer care for optimal case management and prioritization.
Uniquely miR
Accurately detect and risk-classify Prostate Cancer, giving patients and providers confidence in the information used to plan management or treatment
The miR Sentinel™ Prostate Cancer Test requires a single, contact-free urine specimen, with no related risk of side effects
The prostate naturally releases molecules into urine, including several different kinds of RNA genetic material that vary depending on the absence or presence and severity of prostate cancer. This information obtained from the urine sample is all miR Scientific needs to accurately detect and classify cancer using the miR Sentinel Prostate Cancer Test – it is not reliant on clinical risk factors such as PSA, DRE or biopsy material
The miR Sentinel™ Prostate Cancer Test has been validated for the detection and classification of prostate cancer.
miR Sentinel Prostate Cancer Test can replace an array of multiple blood tests, invasive biopsies and imaging procedures with one comprehensive solution.
Unlike biopsies, MRIs and other current options, the miR Disease Management Platform® is high-throughput and can be easily administered for large volumes of patients.
Customer reviews
No reviews were found for miR Scientific - Disease Management Platform. Be the first to review!